Mitogen-activated protein kinase inhibitor regulation of heart function and fibrosis in cardiomyopathy caused by lamin A/C gene mutation

Trends Cardiovasc Med. 2010 Oct;20(7):217-21. doi: 10.1016/j.tcm.2011.11.002.

Abstract

Mutations in the lamin A/C gene (LMNA) encoding A-type nuclear lamins cause dilated cardiomyopathy. We have uncovered a novel connection between these mutations and hyperactivation of the extracellular signal-regulated kinase 1/2 and c-jun N-terminal kinase branches of the mitogen-activated protein kinase signaling pathway in a mouse model of the disease. This discovery has identified targets that can be inhibited by drugs that improve heart function and prevent fibrosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiomyopathy, Dilated / drug therapy
  • Cardiomyopathy, Dilated / enzymology*
  • Cardiomyopathy, Dilated / genetics*
  • Fibrosis
  • Heart / physiopathology
  • Humans
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Lamin Type A / genetics*
  • Mice
  • Mice, Transgenic
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism*
  • Mutation / genetics
  • Myocardium / pathology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Signal Transduction / drug effects
  • Signal Transduction / genetics

Substances

  • LMNA protein, human
  • Lamin Type A
  • Protein Kinase Inhibitors
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases